Buy GTHP for a potential 10 bagger in 2014.
Its cervical cancer scan was recently approved in EU, Canada, Asia, Mid East
Imminent FDA approval will send the shares rocketing.
Over 60 million PAP smear tests are taken annually.
GTHP's biophotonic scan is noninvasive, more accurate and produces instant test results.
The market cap is only $30 million ..... get in on the ground floor.